The Danish Neuro-Oncology Registry

Figures & data

Table 1 List of relevant ICD-10 codes for DNOR and SNOMED M-codes, which defines the inclusion criteria for calculation of indicators in DNOR

Groups	ICD-10 codes	SNOMED M-codes
Cerebral tumors	DD33.0–33.2	M93813,
	DD33.7	M93823,
	DD33.9	M93841,
	DD43.0–43.2	M93853,
	DD43.7+9	M94003,
	DC71.0–71.9	M94013,
	DC72.8	M94113,
	DC72.9	M94213,
		M94243,
		M94253,
		M94403,
		M94423,
		M94503,
		M94513
Meningioma	DD32.0–32.9
	DD42.0–42.9
	DC70.0–9
Sellae tumors	DD35.2
	DD35.3
	DD44.3
	DD44.4
	DD75.1
	DD75.2
Pineal tumors	DD35.4
	DD44.5
	DD75.3
Neurinoma	DD33.3
	DD43.3
	DC72.2–72.5
Spinal tumors	DD33.4
	DD43.4
	DC72.0–72.1

Abbreviations: DNOR, Danish Neuro-Oncology Registry; ICD, International Classification of Diseases; M, morphology; SNOMED, Systematized Nomenclature of Medicine.

Figure 1 Data model of the Danish Neuro-Oncology Registry.

Table 2 Clinical quality indicators used in the Danish Neuro-Oncology Registry

Number	Descriptions	Standards
Ia	Proportion of patients who are alive 1 year after surgery out of all patients in whom the histological diagnosis is glioblastoma	≥50%
Ib	Proportion of patients who are alive 2 years after surgery out of all patients in whom the histological diagnosis is glioblastoma	≥15%
II	Proportion of patients who have undergone postoperative MRI no later than the third day after primary surgery out of all patients who have undergone resection and have contrast-enhancing tumor (ie, suspected high-grade glioma) prior to resection	≥90%
III	Proportion of operations conducted by or supervised by a specialist in neurosurgery out of all operations both primary and at progression	≥95%
IV	Proportion of patients with no measurable residual tumor demonstrated by postoperative MRI performed after primary surgery out of all primarily diagnosed patients, where the histological diagnosis is glioblastoma (ie, denominator includes also those patients with only performed biopsy or where control MRI scan is not available)	≥20% and ≤70%
V	Proportion of patients alive more than 30 days after surgery out of all patients who have undergone primary surgery for gliomas	≥95%
VI	Proportion of patients finishing focal high- dose radiation therapy as planned out of all patients starting this treatment and where the histological diagnosis is glioblastoma	≥90%
VII	Proportion of patients finishing concomitant chemoradiotherapy with temozolomide as planned out of all patients starting this treatment and where the histological diagnosis is glioblastoma	≥85%

Abbreviation: MRI, magnetic resonance imaging.

Table 3 Follow-up data of indicator results in percent

Indicators	Standard	2014	2013	2012	2011	2010
Indicator Ia: Survival, 1 year	≥50%	48 (43–54)	51 (44–57)	45 (39–52)	48 (41–55)	53 (43–64)
Indicator Ib: Survival, 2 years	≥15%	21 (16–26)	19 (14–24)	19 (14–25)	11 (5–19)
Indicator II: Postoperative MRI	≥90%	89 (84–92)	90 (85–93)	82 (76–87)	77 (70–82)	63 (56–70)
Indicator III: Surgical qualifications	≥95%	99 (98–100)	99 (98–100)	96 (94–98)	92 (89–94)	93 (90–95)
Indicator IV: No residual tumor	20%–70%	42 (36–47)	41 (35–47)	26 (21–32)	13 (9–18)	13 (9–18)
Indicator V: Postsurgical survival	≥95%	98 (96–99)	96 (93–98)	98 (96–99)	97 (95–99)	97 (95–99)
Indicator VIb: Radiotherapy	≥90%	92 (87–95)	96 (92–98)	96 (92–99)	97 (93–99)	96 (90–99)
Indicator VIIb: Chemotherapy	≥85%	82 (75–88)	87 (80–91)	90 (84–95)	74 (64–82)	64 (50–76)

Abbreviation: MRI, magnetic resonance imaging.